{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:31:42Z","timestamp":1787841102701,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peyronie\u2019s disease (PD) is a connective tissue disorder characterized by abnormal collagen deposition in the tunica albuginea, leading to penile curvature, pain, and erectile dysfunction. This study aimed to evaluate the outcomes of a combined treatment protocol incorporating collagenase clostridium histolyticum (CCH), vacuum erection device, and tadalafil. A retrospective analysis was conducted on 99 male patients with PD treated at the Department of Urology, Hamad Medical Corporation (Doha, Qatar) between January 2018 and January 2020. Patients received 4\u20138 CCH injections alongside vacuum therapy and daily tadalafil (5 mg). The baseline mean penile curvature of 49.0\u00b0 improved by an average of 21.4% post-treatment. Erectile function scores also increased significantly, with a mean improvement of 2.3 points on the International Index of Erectile Function. Minor complications were observed in 15 patients, while 13 were dissatisfied with treatment, with six opting for surgery. The modified protocol demonstrated significant improvements in penile curvature and erectile function with minimal complications, offering a safe, cost-effective alternative to traditional intensive treatments.<\/jats:p>","DOI":"10.4103\/aja202514","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T10:01:15Z","timestamp":1746180075000},"page":"686-690","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes and management of Peyronie\u2019s disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil"],"prefix":"10.4103","volume":"27","author":[{"given":"Raidh Talib","family":"Alzubaidi","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Urology\/Andrology, Aisha Bint Hamad Al Attiyah Hospital, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdelkareem","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Urology\/Andrology, Aisha Bint Hamad Al Attiyah Hospital, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed M","family":"Al-Zoubi","sequence":"additional","affiliation":[{"name":"Surgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha 3050, Qatar"},{"name":"Department of Biomedical Sciences, QU-Health, College of Health Sciences, Qatar University, Doha 2713, Qatar"},{"name":"Department of Chemistry, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad R","family":"Al-Qudimat","sequence":"additional","affiliation":[{"name":"Surgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha 3050, Qatar"},{"name":"Department of Biomedical Sciences, QU-Health, College of Health Sciences, Qatar University, Doha 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksam","family":"Yasin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Urology\/Andrology, Aisha Bint Hamad Al Attiyah Hospital, Doha 3050, Qatar"},{"name":"Dresden International University, Center of Medicine and Health Sciences, Dresden 01069, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Kamkoum","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Urology\/Andrology, Aisha Bint Hamad Al Attiyah Hospital, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A","family":"Al-Ansari","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Urology\/Andrology, Aisha Bint Hamad Al Attiyah Hospital, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"R1-20251103","first-page":"62","article-title":"Francois Gigot de la Peyronie (1678-1747)","volume":"19","author":"Carson","year":"1981","journal-title":"Invest Urol"},{"key":"R2-20251103","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","article-title":"Psychological impact of Peyronie's disease:a review","volume":"10","author":"Nelson","year":"2013","journal-title":"J Sex Med"},{"key":"R3-20251103","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","article-title":"The chronology of depression and distress in men with Peyronie's disease","volume":"5","author":"Nelson","year":"2008","journal-title":"J Sex Med"},{"key":"R4-20251103","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/sm2.45","article-title":"Psychosexual symptoms and treatment of Peyronie's disease within a collaborative care model","volume":"2","author":"Hartzell","year":"2014","journal-title":"Sex Med"},{"key":"R5-20251103","first-page":"282503","article-title":"A population-based study of Peyronie's disease:prevalence and treatment patterns in the United States","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol. 2011"},{"key":"R6-20251103","first-page":"53","article-title":"Are insulin resistance and non-alcoholic fatty liver disease associated with Peyronie's disease?A pilot study","volume":"73","author":"Crocetto","year":"2022","journal-title":"J Physiol Pharmacol"},{"key":"R7-20251103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/jbcpp-2022-0206","article-title":"Peyronie's disease:where are we at?","volume":"34","author":"Calace","year":"2023","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"R8-20251103","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","article-title":"The management of Peyronie's disease:evidence-based 2010 guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J Sex Med"},{"key":"R9-20251103","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ijir.2011.24","article-title":"Relationship between penile fracture and Peyronie's disease:a prospective study","volume":"23","author":"Acikgoz","year":"2011","journal-title":"Int J Impot Res"},{"key":"R10-20251103","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1097\/01.ju.0000127744.18878.f1","article-title":"Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening","volume":"171","author":"Mulhall","year":"2004","journal-title":"J Urol"},{"key":"R11-20251103","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1743-6109.2011.02502.x","article-title":"Peyronie's disease in teenagers","volume":"9","author":"Tal","year":"2012","journal-title":"J Sex Med"},{"key":"R12-20251103","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/01.ju.0000132144.71458.86","article-title":"Trauma as the cause of Peyronie's disease:penile fracture as a model of trauma","volume":"172","author":"Zargooshi","year":"2004","journal-title":"J Urol"},{"key":"R13-20251103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.sxmr.2018.09.007","article-title":"Review of management options for active-phase Peyronie's disease","volume":"7","author":"Brimley","year":"2019","journal-title":"Sex Med Rev"},{"key":"R14-20251103","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","article-title":"Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction:results from a prospective randomized trial","volume":"35","author":"Palmieri","year":"2012","journal-title":"Int J Androl"},{"key":"R15-20251103","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/andr.13240","article-title":"Impact of extracorporeal shockwave therapy for erectile dysfunction and Peyronie's disease on reproductive and hormonal testicular function","volume":"10","author":"Manfredi","year":"2022","journal-title":"Andrology"},{"key":"R16-20251103","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1743-6109.2007.00614.x","article-title":"Peyronie's disease (CME)","volume":"4","author":"Bella","year":"2007","journal-title":"J Sex Med"},{"key":"R17-20251103","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/andr.12497","article-title":"Collagenase clostridium histolyticum for the treatment of Peyronie's disease:a prospective Italian multicentric study","volume":"6","author":"Capece","year":"2018","journal-title":"Andrology"},{"key":"R18-20251103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.sxmr.2017.03.005","article-title":"Collagenase clostridium histolyticum in the treatment of urologic disease:current and future impact","volume":"6","author":"Gabrielson","year":"2018","journal-title":"Sex Med Rev"},{"key":"R19-20251103","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5534\/wjmh.17033","article-title":"Collagenase clostridium histolyticum in the treatment of Peyronie's disease:review of a minimally invasive treatment option","volume":"35","author":"Gabrielson","year":"2017","journal-title":"World J Mens Health"},{"key":"R20-20251103","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1021\/bi00843a031","article-title":"Purification and partial characterization of collagenolytic enzymes from clostridium histolyticum","volume":"7","author":"Kono","year":"1968","journal-title":"Biochemistry"},{"key":"R21-20251103","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2014.02.1854","article-title":"Pd22-03 collagenase clostridium histolyticum degrades type I and III collagen while sparing type IV collagen in vitro in Peyronie's plaque explants","volume":"191","author":"Levine","year":"2014","journal-title":"J Urol"},{"key":"R23-20251103","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/bju.14784","article-title":"Optimizing collagenase clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling","volume":"124","author":"Fern\u00e1ndez-Pascual","year":"2019","journal-title":"BJU Int"},{"key":"R24-20251103","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"R25-20251103","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/jsm.12871","article-title":"Mesenchymal stem cell therapy for the treatment of erectile dysfunction","volume":"12","author":"Khera","year":"2015","journal-title":"J Sex Med"},{"key":"R26-20251103","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.acuro.2020.06.016","article-title":"Efficacy and safety of collagenase clostridium histolyticum in Peyronie's disease following a modified treatment protocol","volume":"45","author":"Garc\u00eda Cruz","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"R27-20251103","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bju.13932","article-title":"Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol","volume":"120","author":"Abdel","year":"2017","journal-title":"BJU Int"},{"key":"R28-20251103","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","article-title":"Efficacy of combined collagenase clostridium histolyticum and restorex penile traction therapy in men with Peyronie's disease","volume":"16","author":"Alom","year":"2019","journal-title":"J Sex Med"},{"key":"R29-20251103","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JU.0000000000000245","article-title":"Outcomes of a novel penile traction device in men with Peyronie's disease:a randomized, single-blind, controlled trial","volume":"202","author":"Ziegelmann","year":"2019","journal-title":"J Urol"},{"key":"R30-20251103","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/j.1743-6109.2011.02217.x","article-title":"The role of PDE5 inhibitors in penile septal scar remodeling:assessment of clinical and radiological outcomes","volume":"8","author":"Chung","year":"2011","journal-title":"J Sex Med"},{"key":"R31-20251103","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","article-title":"Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction","volume":"183","author":"Ozturk","year":"2014","journal-title":"Ir J Med Sci"},{"key":"R32-20251103","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/0974-7796.152048","article-title":"Tadalafil once daily and intralesional verapamil injection:a new therapeutic direction in Peyronie's disease","volume":"7","author":"Dell'Atti","year":"2015","journal-title":"Urol Ann"},{"key":"R33-20251103","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jsxm.2019.03.404","article-title":"Current strategies in the management of Peyronie's disease (PD)-results of a survey of 401 sexual medicine experts across Europe","volume":"16","author":"Porst","year":"2019","journal-title":"J Sex Med"},{"key":"R34-20251103","first-page":"25","article-title":"Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease","volume":"10","author":"Hatampour","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"R35-20251103","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2021.06.007","article-title":"European Association of Urology guidelines on sexual and reproductive health-2021 update:male sexual dysfunction","volume":"80","author":"Salonia","year":"2021","journal-title":"Eur Urol"},{"key":"R36-20251103","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1743-6109.2008.01104.x","article-title":"Experimental models of Peyronie's disease. Implications for new therapies.","volume":"6","author":"Gonzalez-Cadavid","year":"2009","journal-title":"J Sex Med"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:40:54Z","timestamp":1787838054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202514","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"2024-10-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}